Perspective Therapeutics (CATX) Capital Expenditures (2010 - 2025)

Perspective Therapeutics has disclosed Capital Expenditures across 16 years of filings, most recently posting $51000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at $51000.0, down 99.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $126000.0 (down 99.77% YoY), and the FY2025 annual result was $135000.0, down 99.75% from the prior year.
• Capital Expenditures came in at $51000.0 for Q4 2025 at Perspective Therapeutics, up from $39000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $54.4 million in Q4 2024 to a low of -$10.1 million in Q3 2024.
• The 5-year median for Capital Expenditures is $71500.0 (2021), against an average of $3.1 million.
• Peak annual rise in Capital Expenditures reached 61012.36% in 2024, while the deepest fall reached 1142.8% in 2024.
• Perspective Therapeutics' Capital Expenditures stood at -$86000.0 in 2021, then jumped by 275.58% to $151000.0 in 2022, then plunged by 41.06% to $89000.0 in 2023, then jumped by 61012.36% to $54.4 million in 2024, then slumped by 99.91% to $51000.0 in 2025.
• The last three Capital Expenditures figures came in at $51000.0 (Q4 2025), $39000.0 (Q3 2025), and $36000.0 (Q2 2025), per Business Quant data.